NICE - calculation of cardiovascular disease (CVD) risk in chronic kidney disease (CKD)

Last reviewed 01/2018

People with CKD

• do not use a risk assessment tool to assess CVD risk in people with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 and/or albuminuria. These people are at increased risk of CVD
• offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
  • increase thedose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 ml/min/1.73 m2 or more
  • agree the use of higher doses with a renal specialist if eGFR is less than 30 ml/min/ 1.73 m2

Reference:

• NICE (July 2014). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease